Drugs / [18F]MNI-1054
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03695926 | Aug 2018 → May 2019 | — | Invicro | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04202497 | Dec 2019 → Mar 2020 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT03719482 | Oct 2018 → May 2019 | — | Invicro | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]MNI-1054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03695926 ↗ |
| Modality | Diagnostic / imaging agent | “a novel PET ligand for lysine-specific histone demethylase 1 A (LSD1)” PMID 42397656 ↗ Jul 2026 |
| Route | Intravenous | “Participants will also receive 10 millicurie (mCi) of \[18F\]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3.” NCT04202497 ↗ |